News | Prostate Cancer | June 15, 2017

Prostate PET/CT Targets More Cancer and Improves Patient Care

Molecular imaging pinpoints a greater extent of disease and changes the course of clinical management in more than half of patients

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific molecular imaging gives these men a fighting chance, especially if their cancer returns, according to research revealed at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

This is the first prospective study to include far-reaching data from four Australian medical centers and several hundred patients examined over the course of 18 months. For this study, prostate cancer patients underwent PET/CT--a combination of positron emission tomography and computed tomography. This groundbreaking research shows that prostate-specific molecular imaging led to the detection of cancer that had not been caught by more conventional imaging. Prostate-specific PET/CT subsequently changed the course of treatment plans for 51 percent of patients.

"Prostate-specific PET/CT is a game changer in the evaluation of patients with prostate cancer and has been consistently shown to represent a substantial improvement over conventional imaging for the staging of disease," said Paul J. Roach, MBBS, head of the Department of Nuclear Medicine at Royal North Shore Hospital in Sydney, Australia.

Nuclear Medicine specialists performed PET/CT in concert with an injected imaging agent comprised of a tiny amount of a radioactive material called gallium-68 (Ga-68) and a molecular compound called prostate specific membrane antigen (PSMA). Once administered, the agent zeros in on areas where the PSMA protein is being over-expressed on cell surfaces--including cancer that has spread from the prostate to other organs. The radioactive markers distributed across these areas of PSMA over-expression emit a signal that is picked up by the PET scanner and used to create a highly accurate map of disease.

Referring physicians completed intended treatment surveys prior to PET/CT imaging and once again after the results of imaging were in for a total of 431 patients in this study conducted between January 2015 and June 2016. The change in clinical management was especially remarkable in patients showing signs of recurrent disease--61 percent of treatment plans overall, including 69 percent for patients who had received radiation therapy and 64 percent of patients who had undergone surgery. Conventional radiographic imaging did not detect disease in nearby lymph nodes in 39 percent of patients, in the prostate bed in 27 percent of patients, and in regions where the cancer had metastasized, in 16 percent of patients. Primary screening of intermediate and high-risk prostate cancer led to a change in clinical management in 23 percent of cases.

This and further research could provide the data needed for governments to fund and insurers to approve this new advanced molecular imaging procedure.

"This is likely to become the primary imaging test for many patients with prostate cancer and will replace conventional imaging in many cases," noted Roach. "Given the prevalence of prostate cancer, this could lead to a significant increase in referrals to nuclear medicine and PET centres for Ga-68 PSMA PET/CT imaging worldwide."

Prostate cancer is the second-most prevalent form of cancer in men in the United States, according to the American Cancer Society. Approximately 161,360 new cases of prostate cancer are estimated for 2017 and as many as 26,730 American men are expected to die from the disease this year.

For more information: www.snmmi.org

Related Content

ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Immune Response Prognostic for Prostate Cancer Survival, Recurrence and Radiotherapy Response
News | Prostate Cancer | October 03, 2017
A new study finds that immune response in prostate cancer may be able to forecast how patients will respond to...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Overlay Init